Cardiac Resynchronization Therapy Global Market Report 2025
상품코드:1825647
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
심장 재동기화 치료(CRT) 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.2%로 85억 6,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 심부전 및 심장병 유병률 증가, 고령 인구 증가, 심혈관 질환 유병률 증가, CRT 치료의 필요성, 심박조율기 및 제세동기 치료의 개선, CRT 치료에 대한 인식 증가 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 기존 심박조율기에 대한 CRT-D 장치의 채택, 첨단 기술의 통합, CRT 치료의 확대, 인공지능의 통합, 머신러닝의 채택 등이 있습니다.
향후 5년간 6.2%의 성장률 전망은 지난번 예측보다 0.5% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰은 아일랜드와 벨기에에서 개발된 양심실 심박조율기 및 CRT-D 장치의 가격을 상승시켜 치료 시작 지연과 임플란트 비용 상승을 초래하여 미국의 심부전 치료에 지장을 초래할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
심혈관 질환의 유병률 증가는 심장 재동기화 치료(CRT) 시장의 성장을 가속할 것으로 예측됩니다. 심혈관 질환(CVD)에는 심장과 혈관에 영향을 미치는 다양한 질환이 포함됩니다. CVD 발생률은 고령화, 건강에 해로운 생활습관, 흡연, 좌식생활, 식습관 등의 요인으로 인해 증가하고 있습니다. 심장 재동기화 치료(CRT)는 동기화된 전기 자극을 통해 심장 수축의 협응력을 향상시켜 심부전과 같은 증상을 치료하는 데 도움이 됩니다. 예를 들어, 2024년 9월 미국 미네소타주 보건국 자료에 따르면, 2023년 미네소타주 성인의 약 30%가 고혈압을 앓고 있으며, 약 140만 명이 고혈압에 걸린 것으로 나타났습니다. 2022년, 고혈압성 질환으로 인한 사망자 수는 14,225명으로 전체 사망자의 약 28%에 달했습니다. 이처럼 심혈관 질환의 유병률 증가가 심장 재동기화 치료(CRT) 시장 수요를 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 심장 재동기화 치료(CRT) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 심장 재동기화 치료(CRT) 시장 : 성장률 분석
세계의 심장 재동기화 치료(CRT) 시장 실적 : 규모와 성장, 2019-2024
세계의 심장 재동기화 치료(CRT) 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 심장 재동기화 치료(CRT) : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 심장 재동기화 치료(CRT) 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
심장 재동기화 치료(CRT)(CRT)-제세동기
심장 재동기화 치료(CRT)(CRT)-페이스메이커
세계의 심장 재동기화 치료(CRT) 시장 연령별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
44세 미만
45-64세
65-84세
85세 이상
세계의 심장 재동기화 치료(CRT) 시장 : 최종 용도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원
심장 케어 센터
외래 수술 센터(ASC)
세계의 심장 재동기화 치료(CRT) 시장 : 세분화 심장 재동기화 치료(CRT)(CRT)-제세동기, 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
싱글 챔버 CRT-D
듀얼 챔버 CRT-D
트리플 챔버 CRT-D
양심실 CRT-D
세계의 심장 재동기화 치료(CRT) 시장 : 세분화 심장 재동기화 치료(CRT)(CRT)- 페이스메이커, 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
싱글 챔버 CRT-P
듀얼 챔버 CRT-P
트리플 챔버 CRT-P
양심실 CRT-P
제7장 지역별/국가별 분석
세계의 심장 재동기화 치료(CRT) 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 심장 재동기화 치료(CRT) 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
심장 재동기화 치료(CRT) 시장 : 경쟁 구도
심장 재동기화 치료(CRT) 시장 : 기업 개요
Abbott Laboratories : 개요, 제품 및 서비스, 전략 및 재무 분석
Medtronic plc : 개요, 제품 및 서비스, 전략 및 재무 분석
Boston Scientific Corporation : 개요, 제품 및 서비스, 전략 및 재무 분석
Terumo Corporation : 개요, 제품 및 서비스, 전략 및 재무 분석
Biotronik SE & Co. KG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Lepu Medical Technology(Beijing) Co. Ltd.
Integer Holdings Corporation
Merit Medical Systems Inc.
LivaNova PLC
MicroPort Scientific Corporation
Sorin Group
Berlin Heart GmbH
EBR Systems Inc.
Corvia Medical Inc.
Recor Medical
Jarvik Heart Inc.
Cardiac Dimensions Inc.
Farapulse Inc.
Osypka Medical GmbH
Japan Medical Device Corporation
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
심장 재동기화 치료(CRT) 시장(2029년) : 새로운 기회를 제공하는 국가
심장 재동기화 치료(CRT) 시장(2029년) : 새로운 기회를 제공하는 부문
심장 재동기화 치료(CRT) 시장(2029년) : 성장 전략
시장 동향에 근거한 전략
경쟁 전략
제36장 부록
LSH
영문 목차
영문목차
Cardiac resynchronization therapy (CRT) is a treatment for heart failure aimed at synchronizing the contractions of the heart's ventricles. This therapy utilizes a biventricular pacemaker to administer electrical impulses to the heart muscle, thereby promoting a more coordinated rhythm of ventricular contractions. It has the potential to alleviate symptoms of heart failure, such as shortness of breath and fatigue, while also enhancing overall cardiac function.
The primary types of cardiac resynchronization therapy include cardiac resynchronization therapy (CRT)-defibrillator and cardiac resynchronization therapy (CRT)-pacemaker. A cardiac resynchronization therapy (CRT) defibrillator is a medical device designed to regulate heartbeats and deliver electrical shocks when irregular heart rhythms occur. These devices are utilized across various age groups, including patients below 44 years, 45-64 years, 65-84 years, and those aged above 85 years, by hospitals, cardiac care centers, and ambulatory surgical centers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The cardiac resynchronization therapy market research report is one of a series of new reports from The Business Research Company that provides cardiac resynchronization therapy market statistics, including cardiac resynchronization therapy industry global market size, regional shares, competitors with a cardiac resynchronization therapy market share, detailed cardiac resynchronization therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac resynchronization therapy industry. This cardiac resynchronization therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cardiac resynchronization therapy market size has grown strongly in recent years. It will grow from $6.29 billion in 2024 to $6.72 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to growth in the geriatric population, an increased incidence of heart failure, growth in investments in R&D for CRT device innovation, increased awareness about the therapy's benefits, physician training programs, and competitive landscape dynamics.
The cardiac resynchronization therapy market size is expected to see strong growth in the next few years. It will grow to $8.56 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the increasing prevalence of heart failure and cardiac disorders, growth in the geriatric population, a higher incidence of cardiovascular diseases, the need for CRT therapy, improvements in pacemakers and defibrillator treatment, and increasing awareness about CRT therapy. Major trends in the forecast period include the adoption of CRT-D devices over traditional pacemakers, the integration of advanced technology, expansion of CRT therapy, the integration of artificial intelligence, and the adoption of machine learning.
The forecast of 6.2% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. heart failure treatment by inflating prices of biventricular pacemakers and CRT-D devices developed in Ireland and Belgium, resulting in delayed therapy initiation and higher implant costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of cardiovascular diseases is expected to drive the growth of the cardiac resynchronization therapy (CRT) market. Cardiovascular diseases (CVD) encompass a range of conditions affecting the heart and blood vessels. The incidence of CVD is increasing due to factors such as aging populations, unhealthy lifestyles, high tobacco use, sedentary behavior, and poor dietary habits. Cardiac resynchronization therapy helps treat conditions like heart failure by improving the coordination of the heart's contractions through synchronized electrical impulses. For example, in September 2024, data from the Minnesota Department of Health, a US-based state health agency, revealed that approximately 30% of adults in Minnesota reported having high blood pressure in 2023, affecting nearly 1.4 million people. In 2022, hypertensive diseases were a contributing cause in 14,225 deaths in the state, accounting for almost 28% of all fatalities. As such, the growing prevalence of cardiovascular diseases is driving the demand for cardiac resynchronization therapy market.
The growing healthcare expenditure is expected to drive the expansion of the cardiac resynchronization therapy (CRT) market. Healthcare expenditure refers to the total spending on healthcare goods and services over a specific period, typically on a national or institutional level. Increased investment in healthcare can foster research and development in the field of cardiac resynchronization therapy, leading to advancements in technology, improved access to therapy, and a more comprehensive approach to healthcare systems. For example, in May 2023, the UK's Office for National Statistics reported a 9.4% nominal increase and a 9.7% practical increase in healthcare spending. In 2021, the UK's total healthcare spending was $367.25 billion (£280.7 billion), with pharmaceutical costs accounting for $51.84 billion (£39.6 billion). Spending on preventative care also surged in 2021, reaching $45.93 billion (£35.1 billion). Additionally, in September 2024, Cross River Therapy, a US-based provider of ABA therapy services, reported that the US pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medicine in 2021. Projections suggest this spending will rise to $605-$635 billion by 2025. As a result, the increasing healthcare expenditure is driving the growth of the cardiac resynchronization therapy market.
Leading companies in the cardiac resynchronization therapy market are concentrating on the development of implantable devices to enhance treatment outcomes for heart failure patients. Implantable devices in CRT synchronize the contractions of the heart's ventricles, improving pumping efficiency and managing heart failure symptoms. For instance, MicroPort Scientific Corporation launched the GALI SonR cardiac resynchronization therapy and defibrillation device (CRT-D) and the Navigo 4LV left ventricular pacing leads in Japan in February 2024. This innovative CRT-D device incorporates the first and only CRT hemodynamic sensor, designed to automatically optimize patients on a weekly basis, even during physical activity, thus ensuring real-life optimization. The clinically proven SonR algorithm has demonstrated a 35% reduction in the risk of heart failure hospitalization, contributing to the well-being and safety of CRT-D patients.
Major companies operating in the cardiac resynchronization therapy market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, Biotronik SE & Co. KG, Lepu Medical Technology (Beijing) Co. Ltd., Integer Holdings Corporation, Merit Medical Systems Inc., LivaNova PLC, MicroPort Scientific Corporation, Sorin Group, Berlin Heart GmbH, EBR Systems Inc., Corvia Medical Inc., Recor Medical, Jarvik Heart Inc., Cardiac Dimensions Inc., Farapulse Inc., Osypka Medical GmbH, Japan Medical Device Corporation, Imricor Medical Systems Inc., Vascular Dynamics Inc., Svelte Medical Systems, Aleva Neurotherapeutics, BioSig Technologies Inc.
North America was the largest region in the cardiac resynchronization therapy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac resynchronization therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cardiac resynchronization therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cardiac resynchronization therapy market consists of revenues earned by entities by providing services such as patient evaluation and diagnosis, device implantation procedures, device programming, follow-up care, management of complications, patient education, and collaborative care involving a multidisciplinary team. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac resynchronization therapy market also includes sales of pacemakers or defibrillators, leads, programmers, accessories, diagnostic tools, patient monitoring devices, and educational materials. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cardiac Resynchronization Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cardiac resynchronization therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cardiac resynchronization therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiac resynchronization therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
3. Cardiac Resynchronization Therapy Market Trends And Strategies
4. Cardiac Resynchronization Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Cardiac Resynchronization Therapy Growth Analysis And Strategic Analysis Framework
5.1. Global Cardiac Resynchronization Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Cardiac Resynchronization Therapy Market Growth Rate Analysis
5.4. Global Cardiac Resynchronization Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Cardiac Resynchronization Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Cardiac Resynchronization Therapy Total Addressable Market (TAM)
